Mount Yale Investment Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mount Yale Investment Advisors LLC trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 62.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,673 shares of the biopharmaceutical company’s stock after selling 9,305 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $271,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. SWP Financial LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter worth about $366,000. Marshall Financial Group LLC bought a new position in Halozyme Therapeutics during the 4th quarter worth approximately $1,530,000. First Citizens Bank & Trust Co. increased its stake in shares of Halozyme Therapeutics by 16.9% in the fourth quarter. First Citizens Bank & Trust Co. now owns 4,704 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 681 shares during the period. Janney Montgomery Scott LLC increased its position in shares of Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after acquiring an additional 251,711 shares during the period. Finally, Sugar Maple Asset Management LLC purchased a new position in Halozyme Therapeutics during the 4th quarter valued at about $373,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on HALO shares. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Price Performance

HALO stock opened at $55.83 on Thursday. The company’s fifty day moving average price is $50.28 and its 200-day moving average price is $54.28. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a market capitalization of $7.10 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.